Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
03.11.2023 - Cloak and Dagger Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T CellsData from Preclinical Study of Cloak Technology Highlights Ability to Engineer Allogeneic Cells to Evade ... Seite 1
Werewolf Therapeutics, Inc. announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company?s lead clinical program, WTX-124x2101. This clinical...
Funda Meric-Bernstam, MD, discusses results from the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki in HER2-expressing solid tumors.
The safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib.
Initial Results From A Phase 1 Study of CFT8634, A Novel Bifunctional Degradation Activating Compound of BRD9, in Synovial Sarcoma and SMARCB1-Null Tumors ...